Literature DB >> 16831960

Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders.

Helmar C Lehmann1, Hans-Peter Hartung, Gerd R Hetzel, Olaf Stüve, Bernd C Kieseier.   

Abstract

Plasma exchange is a well-established therapeutic procedure commonly used in many neurological disorders of autoimmune etiology. It is thought that the beneficial effects of plasma exchange occur through the elimination of pathognomonic inflammatory mediators, including autoantibodies, complement components, and cytokines. In various neurological disorders, randomized controlled studies have demonstrated the efficacy of plasma exchange (eg, in Guillain-Barré syndrome and other forms of immune neuropathies). Although widely used, the potential benefit of plasma exchange in the treatment of multiple sclerosis, myasthenia gravis, and Lambert-Eaton syndrome is less clear.

Entities:  

Mesh:

Year:  2006        PMID: 16831960     DOI: 10.1001/archneur.63.7.930

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  35 in total

1.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Ozgür Yaldizli; Norman Putzki
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 2.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

Review 3.  Corticosteroids and plasma exchange in multiple sclerosis.

Authors:  Hayretin Tumani
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

4.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

5.  Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases.

Authors:  Anil Tombak; Mehmet Ali Uçar; Aydan Akdeniz; Arda Yilmaz; Hakan Kaleagası; Mehmet Ali Sungur; Eyup Naci Tiftik
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-22       Impact factor: 0.900

6.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 7.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

8.  Therapeutic strategies in childhood multiple sclerosis.

Authors:  Angelo Ghezzi
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 9.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

10.  Role of anti-GQ1B antibody in differential diagnosis of acute ophthalmoparesis.

Authors:  E Ece Boylu; R Erdem Toğrol; Mehmet Güney Senol; M Fatih Ozdağ; Mehmet Saraçoğlu
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.